Hahn Capital Management LLC Sells 412 Shares of Becton, Dickinson and Company $BDX

Hahn Capital Management LLC cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,336 shares of the medical instruments supplier’s stock after selling 412 shares during the period. Becton, Dickinson and Company makes up approximately 2.2% of Hahn Capital Management LLC’s investment portfolio, making the stock its 22nd largest holding. Hahn Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $4,709,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC lifted its holdings in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. Versant Capital Management Inc lifted its stake in Becton, Dickinson and Company by 27.4% in the first quarter. Versant Capital Management Inc now owns 265 shares of the medical instruments supplier’s stock valued at $61,000 after buying an additional 57 shares in the last quarter. NBC Securities Inc. bought a new position in Becton, Dickinson and Company in the first quarter valued at approximately $102,000. Merit Financial Group LLC lifted its stake in Becton, Dickinson and Company by 54.3% in the first quarter. Merit Financial Group LLC now owns 5,846 shares of the medical instruments supplier’s stock valued at $1,339,000 after buying an additional 2,058 shares in the last quarter. Finally, HF Advisory Group LLC lifted its stake in Becton, Dickinson and Company by 60.4% in the first quarter. HF Advisory Group LLC now owns 5,109 shares of the medical instruments supplier’s stock valued at $1,170,000 after buying an additional 1,924 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,023 shares of company stock valued at $562,036. Corporate insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on BDX shares. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Piper Sandler restated a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Morgan Stanley boosted their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Royal Bank Of Canada started coverage on Becton, Dickinson and Company in a research note on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 target price on the stock. Finally, Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $205.40.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $191.43 on Friday. The stock has a 50 day moving average price of $188.87 and a 200 day moving average price of $187.95. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The stock has a market capitalization of $54.87 billion, a PE ratio of 34.43, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were paid a $1.04 dividend. The ex-dividend date was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.